Clinical trials: Melanoma Metastatic
Malignant Melanoma
Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
The purpose of this study is to determine whether a medication, fluvastatin, can change melanoma to a state that is less likely to metastasize or recur.
- Trial name
- NCT04285749
- Testing
- Fluvastatin, RNA-sequencing, Gene expression profiling
- Sponsor
- Case Comprehensive Cancer Center
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV…
- Trial name
- NCT00012064
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Lisata Therapeutics, Inc.
Positron-Emission Tomography, Immunomodulation
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to…
- Conditions
- Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
- Trial name
- NCT03107663
- Testing
- ⁸⁹Zr-Df-IAB22M2C Infusion
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- ImaginAb, Inc.
Metastatic Melanoma
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma
This is an open bi-centric prospective non-randomized study in patients with metastatic melanoma treated with a first line treatment of Nivolumab +/- Ipilimumab.
- Trial name
- IMMUNONIVO (NCT03225365)
- Testing
- Blood and biopsy sampling
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Hospices Civils de Lyon
Melanoma
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with…
- Trial name
- NCT03635983
- Testing
- NKTR-214, Nivolumab
- Where
- 167 sites in United States, Argentina and 25 more
- Volunteers
- 783 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Melanoma
Long-term Data Collection for Subjects in MDX-010 Studies
The objective of this study is to collect disease status and overall survival information for all Subjects in MDX-010 studies.
- Trial name
- MDX010-28 (NCT00928031)
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
- Trial name
- NCT02302339
- Testing
- glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
- Where
- 14 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Malignant Melanoma
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
This open-label single arm study will assess the efficacy, safety and tolerability of Vemurafenib in previously treated patients with metastatic melanoma.
- Trial name
- NCT00949702
- Testing
- vemurafenib
- Where
- 15 sites in United States, Australia
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
The purpose of this study is to determine the effects of combination treatment of Nivolumab with Ipilimumab followed by Nivolumab monotherapy in patients with previously untreated advanced Melanoma.
- Trial name
- CheckMate 401 (NCT02599402)
- Testing
- Nivolumab, Ipilimumab
- Where
- 111 sites in Australia, Austria and 10 more
- Volunteers
- 533 people
- Sponsor
- Bristol-Myers Squibb
Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma
Early FDG PET in Melanoma
Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy.
- Trial name
- NCT02716077
- Testing
- FDG PET/CT imaging
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Melanoma
Markers of Efficacy to Immunotherapy in Patients With Metastatic Melanoma
Cutaneous melanoma is an aggressive malignancy with a rising global incidence; its prognosis has been radically transformed by immune checkpoint inhibitors (ICIs), a class of immunotherapeutic agents targeting immune regulatory…
- Trial name
- PREMIO (NCT07794501)
- Volunteers
- 200 people
- Sponsor
- European Institute of Oncology
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
This phase I trial studies the side effects and best dose of a modified virus called VSV-IFNbetaTYRP1 in treating patients with stage III-IV melanoma.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Choroid Melanoma, Metastatic Melanoma
- Trial name
- NCT03865212
- Testing
- Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Melanoma
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT06190951
- Testing
- cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab
- Where
- 104 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Regeneron Pharmaceuticals
Cutaneous Malignant Melanoma
Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma
This is a multicenter, randomized, double-blind, placebo-controlled phase I/II trial designed to characterize the safety and estimate the efficacy of nintedanib when combined with paclitaxel chemotherapy compared with paclitaxel…
- Trial name
- NIPAWILMA (NCT02308553)
- Testing
- Nintedanib, Paclitaxel
- Where
- 10 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
Melanoma (Skin)
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir.
- Trial name
- NCT00005057
- Testing
- adenovirus RSV-TK, ganciclovir
- Where
- 3 sites in United States
- Sponsor
- National Human Genome Research Institute (NHGRI)
Malignant Melanoma Stage IV
[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
The goal of this clinical trial is to investigate the use of the tracer [68Ga]Ga-FAPI-46 for PET/CT-imaging in response evaluation of patients with advanced stage malignant melanoma treated with immune checkpoint inhibitor…
- Trial name
- BEFAST (NCT07215182)
- Testing
- [68Ga]Ga-FAPI-46
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Barbara Malene Fischer
Metastatic Melanoma, Malignant Metastatic Melanoma
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
- Conditions
- Metastatic Melanoma, Malignant Metastatic Melanoma, Advanced Melanoma, Melanoma
- Trial name
- NCT01212276
- Testing
- MORAb-028
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Morphotek
Melanoma (Skin)
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
The goal of this study is to observe metabolic features associated with human melanoma tumors.
- Trial name
- NCT06400550
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Melanoma
Multicenter Tissue Registry in Melanoma
The prospective multicenter translational study Tissue Registry in Melanoma (ADOREG/TRIM; CA209-578) aimed to validate the Tumor Mutational Burden (TMB) and the PD-L1 expression (PD-L1) from a pre-therapeutically obtained tumor…
- Trial name
- TRIM (NCT05750511)
- Testing
- molecular tissue analysis
- Where
- 14 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- Dermatologic Cooperative Oncology Group